NCT00001371已完成不适用
A Pilot Study of Topical Antiflammin-2 for Psoriasis
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 24
- 试验地点
- 1
研究概览
简要总结
This study is a pilot trial designed to evaluate topical antiflammin-2, a phospholipase A2 (PLA2) inhibitor, in the treatment of chronic plaque psoriasis. Antiflammin-2 in an ointment base, or the vehicle alone will each be applied four times per day to a single plaque in a randomized, double-blinded fashion.
详细描述
This study is a pilot trial designed to evaluate topical antiflammin-2, a phospholipase A2 (PLA2) inhibitor, in the treatment of chronic plaque psoriasis. Antiflammin-2 in an ointment base, or the vehicle alone will each be applied four times per day to a single plaque in a randomized, double-blinded fashion.
研究设计
- 研究类型
- Observational
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Atopic DermatitisAtopic DermatitisNCT06144424Escient Pharmaceuticals, Inc30
已完成
2 期
Efficacy and Safety of Tazarotene Gel in Nail PsoriasisNail PsoriasisNCT02235480Almirall, S.A.66
已完成
2 期
Phase II Study Assessing Safety and Efficacy of APL-2 in GlomerulopathiesIgA NephropathyC3 GlomerulonephritisMembranous NephropathyDense Deposit DiseaseLupus NephritisNCT03453619Apellis Pharmaceuticals, Inc.21
已完成
2 期
Safety and Efficacy of Multiple Doses of BT061 in Patients With Moderate to Severe Chronic Plaque PsoriasisPsoriasis VulgarisNCT01072383Biotest49
已完成
2 期
Anti-Tac(Fv)-PE38 (LMB-2) to Treat Cutaneous T-Cell LymphomasT-CellCutaneousLymphomaNCT00080535National Cancer Institute (NCI)10